Corvus Pharmaceuticals vs Spyre Therapeutics
CRVS and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVS and SYRE compare
Spyre Therapeutics is the larger company, worth 10 times as much as Corvus Pharmaceuticals ($8.5B against $844M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVS | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $844M | $8.5B |
| Share price | $10.03 | $96.56 |
| Change, 1 year | 30.6% | 305% |
| Change, 5 years | 101% | −47.2% |
| Beta (5Y) | 1.18 | 1.47 |
| Employees | 37 | 102 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.7× (better) | 7.7× |
| FCF yield | −5.4% | – |
| Profitability | ||
| Return on equity | −35.4% | −23.0% (better) |
| Return on invested capital | −564% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.16 | 18.53 (better) |
| Altman Z-score | 33.96 | 70.18 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.1% | 109% |
| Held by insiders | 30.5% | 20.4% |
| Insider net buying, 12 months | $334K (better) | −$437M |
| Short interest, % of float | 30.5% | 18.3% |
Go deeper
- CRVS stock overview
- CRVS income statement
- CRVS valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.